Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Overview

This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and their effect on blood glucose control, versus insulin glargine alone as active comparator in type 2 diabetes.

Full Title of Study: “Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2008

Detailed Description

Due to the different mechanisms of action of the long-acting insulin analog insulin glargine and both a GLP-1 analog (exenatide) and a DPP-4-inhibitor (sitagliptin), it could be a promising approach to combine insulin glargine with either exenatide or sitagliptin for optimum control of fasting and postprandial blood glucose values. Thus, in the present study the influence of either exenatide or sitagliptin as a 4-week adjunctive therapy to a basal insulin (insulin glargine) was investigated versus insulin glargine alone as active comparator in subjects with type 2 diabetes. Preexisting metformin was continued, sulfonylureas, if any, were stopped. In particular, the effects on postprandial blood glucose excursion following ingestion of a standard breakfast, assessed after 4 weeks of treatment, the effects on mean daily blood glucose, on self-measured 7-point profiles, the percentage of subjects reaching ADA treatment goals (HbA1c < 7.0%) at the end of treatment, on fasting lipid profile, on HOMA index, weight, hypoglycemic episodes and general safety were assessed. The study consisted of a screening visit, a 4-8 week (depending on pre-treatment) run-in period, a 4-week treatment period, and a follow-up visit. There were weekly visits at the site and twice weekly telephone contacts.

Interventions

  • Drug: insulin glargine + exenatide + preexisting metformin
    • insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
  • Drug: insulin glargine + sitagliptin + preexisting metformin
    • insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
  • Drug: insulin glargine + preexisting metformin
    • insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin

Arms, Groups and Cohorts

  • Experimental: insulin glargine + exenatide + metformin
  • Experimental: Insulin glargine + sitagliptin + metformin
  • Active Comparator: insulin glargine + metformin

Clinical Trial Outcome Measures

Primary Measures

  • the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast
    • Time Frame: after 4 weeks of treatment

Secondary Measures

  • mean daily blood glucose (BG) from 7-point 24h BG profiles, fasting BG, self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid profiles, HOMA-IR index, hypoglycemic episodes
    • Time Frame: after 4 weeks of treatment

Participating in This Clinical Trial

Inclusion Criteria

  • male or female subjects aged between 35 and 70 years, inclusive – type 2 diabetes with duration >6 months and <10 years – for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas – HbA1c >=7.0% and <=10.0% – if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start – written informed consent Exclusion Criteria:

  • history or presence of cancer or any clinically relevant diseases – chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial infarction within the previous 6 months – recurrent hypoglycemia – abnormal lab tests at screening (ALAT and/or ASAT >=3 times ULN), creatinine >1.6 mg/dL in males and >1.4 mg/dL in females – clinically relevant ECG findings at screening – treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months – treatment with any other OHA than metformin or metformin plus sulfonylureas during the previous 3 months – any systemic or topical treatment with drugs known to influence glucose metabolism

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Profil Institut für Stoffwechselforschung GmbH
  • Collaborator
    • Sanofi
  • Provider of Information About this Clinical Study
    • Christoph Kapitza, MD, Profil Institut für Stoffwechselforschung GmbH
  • Overall Official(s)
    • Sabine Arnolds, MD, Principal Investigator, Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.